ASND
Ascendis Pharma A/S NASDAQ Listed Jan 28, 2015$230.83
-0.14%
vs $231.15
Mkt Cap $14.3B
52w Low $160.86
77.8% of range
52w High $250.74
50d MA $231.76
200d MA $217.83
P/E (TTM)
-63.8x
EV/EBITDA
—
P/B
—
Debt/Equity
-5.3x
ROE
—
P/FCF
320.7x
RSI (14)
56.10
ATR (14)
$8.52
Beta
0.48
50d MA
$231.76
200d MA
$217.83
Avg Volume
628.2K
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Tuborg Boulevard 12 · Hellerup 2900 · DK
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 11, 2026 | AMC | -0.06 | -0.64 | -966.7% | 221.49 | -4.7% | -1.5% | -0.8% | +3.3% | +1.5% | +1.5% | — |
| Nov 12, 2025 | AMC | -0.41 | -1.17 | -185.4% | 199.22 | -3.5% | +3.6% | -1.0% | +5.9% | +0.3% | -2.3% | — |
| Aug 7, 2025 | AMC | -1.42 | -0.93 | +34.5% | 190.35 | +3.8% | +0.6% | +2.3% | +0.0% | -2.5% | +0.5% | — |
| May 1, 2025 | AMC | -1.56 | -1.66 | -6.4% | 167.47 | +0.3% | +2.7% | -0.8% | -4.6% | -1.1% | -1.0% | — |
| Feb 12, 2025 | AMC | -1.20 | -0.68 | +43.3% | 126.14 | +10.0% | +13.0% | +1.1% | +8.4% | -0.7% | -0.3% | — |
| Nov 14, 2024 | AMC | -1.83 | -1.81 | +1.2% | 124.28 | -4.3% | +1.8% | -3.6% | +2.0% | -0.0% | -1.4% | — |
| Sep 3, 2024 | AMC | -1.54 | -2.05 | -33.1% | 134.68 | -13.1% | -11.3% | -0.4% | +0.1% | -1.9% | -1.8% | — |
| May 2, 2024 | AMC | -1.62 | -2.48 | -53.3% | 141.10 | +0.6% | -2.8% | -2.3% | +1.5% | -1.5% | -0.6% | — |
| Feb 7, 2024 | AMC | -2.19 | -1.66 | +24.1% | 139.29 | +1.1% | -0.0% | +1.8% | +2.0% | -0.9% | +2.3% | — |
| Nov 7, 2023 | AMC | -2.55 | -3.08 | -21.0% | 96.15 | -1.8% | -1.5% | -2.8% | -1.9% | -0.9% | +5.9% | — |
| Aug 16, 2023 | AMC | -3.09 | -1.54 | +50.2% | 89.90 | +0.1% | -2.2% | +2.9% | +3.3% | -1.1% | +1.6% | — |
| Apr 27, 2023 | AMC | -2.93 | -2.18 | +25.6% | 76.98 | -0.6% | -9.1% | +24.0% | -0.9% | +6.5% | +2.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 19 | Citigroup | Initiates | Buy | $355 | $237.64 | $237.83 | +0.1% | +0.1% | +1.4% | +2.6% | -0.2% | -3.0% |
| Apr 16 | BofA Securities | Maintains | Buy → Buy | — | $241.71 | $241.71 | +0.0% | +0.5% | +0.6% | +0.4% | -2.1% | -3.8% |
| Apr 9 | Wedbush | Maintains | Outperform → Outperform | — | $233.20 | $233.20 | +0.0% | +3.6% | -1.0% | +3.9% | +0.5% | -3.3% |
| Mar 3 | RBC Capital | Maintains | Outperform → Outperform | — | $242.09 | $235.80 | -2.6% | -1.2% | +0.9% | -1.7% | +1.4% | -0.3% |
| Feb 12 | Wedbush | Maintains | Outperform → Outperform | — | $221.49 | $211.00 | -4.7% | -1.5% | -0.8% | +3.3% | +1.5% | +1.5% |
| Feb 12 | Oppenheimer | Maintains | Outperform → Outperform | — | $221.49 | $211.00 | -4.7% | -1.5% | -0.8% | +3.3% | +1.5% | +1.5% |
| Jan 30 | BofA Securities | Maintains | Buy → Buy | — | $223.95 | $224.00 | +0.0% | +1.0% | -1.1% | +0.5% | -2.2% | -1.1% |
| Jan 20 | Wells Fargo | Maintains | Overweight → Overweight | — | $205.83 | $203.51 | -1.1% | +4.7% | +0.5% | +5.5% | +2.9% | -0.7% |
| Jan 20 | RBC Capital | Maintains | Outperform → Outperform | — | $205.83 | $203.51 | -1.1% | +4.7% | +0.5% | +5.5% | +2.9% | -0.7% |
| Jan 9 | Wells Fargo | Maintains | Overweight → Overweight | — | $208.75 | $213.24 | +2.2% | -2.8% | +2.8% | +3.0% | +1.1% | -1.0% |
| Jan 7 | TD Cowen | Maintains | Buy → Buy | — | $209.29 | $209.61 | +0.2% | +1.9% | -2.1% | -2.8% | +2.8% | +3.0% |
| Dec 11 | Stifel | Maintains | Buy → Buy | — | $201.24 | $203.69 | +1.2% | +4.4% | +4.9% | -3.3% | -0.5% | -4.4% |
| Nov 18 | Wedbush | Maintains | Outperform → Outperform | — | $216.56 | $221.89 | +2.5% | +0.3% | -2.3% | -1.2% | +0.4% | -0.7% |
| Oct 13 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $209.55 | $214.06 | +2.2% | -0.5% | +0.1% | -0.8% | -0.0% | +1.7% |
| Oct 9 | JP Morgan | Maintains | Overweight → Overweight | — | $210.13 | $210.00 | -0.1% | +2.2% | -2.4% | -0.5% | +0.1% | -0.8% |
| Sep 2 | BofA Securities | Maintains | Buy → Buy | — | $194.27 | $195.50 | +0.6% | +2.5% | +0.4% | -0.9% | +3.9% | -0.3% |
| Aug 19 | JP Morgan | Maintains | Overweight → Overweight | — | $194.08 | $192.74 | -0.7% | +0.3% | -0.9% | +0.0% | +0.8% | -2.0% |
| Aug 8 | RBC Capital | Maintains | Outperform → Outperform | — | $190.35 | $197.58 | +3.8% | +0.6% | +2.3% | +0.0% | -2.5% | +0.5% |
| Aug 8 | Citigroup | Maintains | Buy → Buy | — | $190.35 | $197.58 | +3.8% | +0.6% | +2.3% | +0.0% | -2.5% | +0.5% |
| Aug 8 | Stifel | Maintains | Buy → Buy | — | $190.35 | $197.58 | +3.8% | +0.6% | +2.3% | +0.0% | -2.5% | +0.5% |
| Aug 8 | UBS | Maintains | Buy → Buy | — | $190.35 | $197.58 | +3.8% | +0.6% | +2.3% | +0.0% | -2.5% | +0.5% |
| Aug 8 | Wells Fargo | Maintains | Overweight → Overweight | — | $190.35 | $197.58 | +3.8% | +0.6% | +2.3% | +0.0% | -2.5% | +0.5% |
| Aug 8 | Wedbush | Maintains | Outperform → Outperform | — | $190.35 | $197.58 | +3.8% | +0.6% | +2.3% | +0.0% | -2.5% | +0.5% |
| Aug 8 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $190.35 | $197.58 | +3.8% | +0.6% | +2.3% | +0.0% | -2.5% | +0.5% |
| Jul 29 | JP Morgan | Maintains | Overweight → Overweight | — | $164.16 | $164.27 | +0.1% | -0.5% | +2.1% | +4.0% | +0.6% | +5.5% |
| Jul 11 | Citigroup | Maintains | Buy → Buy | — | $176.49 | $176.42 | -0.0% | -0.9% | -0.0% | -0.1% | +0.4% | +1.0% |
| Jun 13 | Oppenheimer | Maintains | Outperform → Outperform | — | $170.92 | $170.18 | -0.4% | -0.1% | +4.0% | -2.7% | -1.3% | +3.6% |
| Jun 9 | BofA Securities | Maintains | Buy → Buy | — | $173.06 | $175.85 | +1.6% | +0.1% | -0.5% | -0.4% | -0.5% | -0.1% |
| Jun 3 | BofA Securities | Maintains | Buy → Buy | — | $175.69 | $176.34 | +0.4% | -0.7% | -0.4% | +2.2% | -2.5% | +0.1% |
| May 12 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $151.25 | $153.41 | +1.4% | +2.1% | +4.6% | -2.7% | +0.2% | +0.0% |
| May 5 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $172.06 | $175.60 | +2.1% | -0.8% | -4.6% | -1.1% | -1.0% | -5.1% |
| May 2 | JP Morgan | Maintains | Overweight → Overweight | — | $167.47 | $168.00 | +0.3% | +2.7% | -0.8% | -4.6% | -1.1% | -1.0% |
| May 2 | Evercore ISI | Maintains | Outperform → Outperform | — | $167.47 | $168.00 | +0.3% | +2.7% | -0.8% | -4.6% | -1.1% | -1.0% |
| May 2 | RBC Capital | Maintains | Outperform → Outperform | — | $167.47 | $168.00 | +0.3% | +2.7% | -0.8% | -4.6% | -1.1% | -1.0% |
| May 2 | Oppenheimer | Maintains | Outperform → Outperform | — | $167.47 | $168.00 | +0.3% | +2.7% | -0.8% | -4.6% | -1.1% | -1.0% |
| May 2 | Wedbush | Maintains | Outperform → Outperform | — | $167.47 | $168.00 | +0.3% | +2.7% | -0.8% | -4.6% | -1.1% | -1.0% |
| Mar 18 | JP Morgan | Maintains | Overweight → Overweight | — | $168.84 | $168.01 | -0.5% | -2.5% | +0.9% | -1.7% | +1.7% | +1.2% |
| Feb 25 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $151.06 | $151.94 | +0.6% | +0.3% | +0.7% | +0.3% | +2.2% | -3.0% |
| Feb 18 | Evercore ISI | Maintains | Outperform → Outperform | — | $144.08 | $145.48 | +1.0% | +8.4% | -0.7% | -0.3% | -1.4% | -0.9% |
| Feb 13 | JP Morgan | Maintains | Overweight → Overweight | — | $126.14 | $138.75 | +10.0% | +13.0% | +1.1% | +8.4% | -0.7% | -0.3% |
| Feb 13 | Goldman Sachs | Maintains | Buy → Buy | — | $126.14 | $138.75 | +10.0% | +13.0% | +1.1% | +8.4% | -0.7% | -0.3% |
| Feb 11 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $119.49 | $118.22 | -1.1% | +0.0% | +5.5% | +13.0% | +1.1% | +8.4% |
| Jan 29 | JP Morgan | Maintains | Overweight → Overweight | — | $129.37 | $129.94 | +0.4% | -1.4% | -0.2% | +2.6% | -4.3% | -2.3% |
| Nov 15 | Oppenheimer | Maintains | Outperform → Outperform | — | $124.28 | $118.98 | -4.3% | +1.8% | -3.6% | +2.0% | -0.0% | -1.4% |
| Nov 15 | Wedbush | Maintains | Outperform → Outperform | — | $124.28 | $118.98 | -4.3% | +1.8% | -3.6% | +2.0% | -0.0% | -1.4% |
| Nov 15 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $124.28 | $118.98 | -4.3% | +1.8% | -3.6% | +2.0% | -0.0% | -1.4% |
| Nov 15 | TD Cowen | Maintains | Buy → Buy | — | $124.28 | $118.98 | -4.3% | +1.8% | -3.6% | +2.0% | -0.0% | -1.4% |
| Nov 15 | Stifel | Maintains | Buy → Buy | — | $124.28 | $118.98 | -4.3% | +1.8% | -3.6% | +2.0% | -0.0% | -1.4% |
| Nov 4 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $125.28 | $127.20 | +1.5% | +0.4% | +1.9% | +1.0% | -2.2% | -1.8% |
| Oct 23 | JP Morgan | Maintains | Overweight → Overweight | — | $129.07 | $128.73 | -0.3% | -1.1% | +1.7% | +0.4% | -0.7% | -2.1% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 2, 2026 | SMITH SCOTT THOMAS | EVP & Chief Financial Officer | Buy | 100 | $219.00 | $22K | 4,367 | +0.09% | +3.61% |
| May 29, 2026 | SMITH SCOTT THOMAS | EVP & Chief Financial Officer | Buy | 250 | $223.32 | $56K | 4,267 | -1.01% | -2.20% |
| May 29, 2026 | BIENAIME JEAN JACQUES | — | Buy | 100 | $223.50 | $22K | 900 | -1.01% | -2.20% |
| May 29, 2026 | BIENAIME JEAN JACQUES | — | Buy | 200 | $223.76 | $45K | 600 | -1.01% | -2.20% |
| May 26, 2026 | BIENAIME JEAN JACQUES | — | Buy | 200 | $236.24 | $47K | 200 | +0.94% | +0.09% |
| May 11, 2026 | JENSEN FLEMMING STEEN | See Remarks | Sell | 19,460 | $238.49 | $4.6M | — | +2.50% | +0.14% |
No recent filings available.
Institutional (13F) — Top 0
All ↗
No 13F holders found.
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$14.34B
Enterprise Value
$13.76B
P/E (TTM)
-63.77x
Forward P/E
58.23x
PEG Ratio
1.13x
P/B
—
P/S
20.23x
P/FCF
320.73x
EV/EBITDA
—
Shares Out
60.6M
Financials (TTM)
Revenue
$691.7M
Net Income
-$219.0M
EBITDA
-$113.9M
Free Cash Flow
$43.6M
Op Cash Flow
$51.8M
EPS Basic
$-3.62
EPS Diluted
$-3.62
EPS Forward
$3.96
Gross Margin
85.1%
Op Margin
-18.9%
Net Margin
-31.7%
Balance Sheet
Total Assets
$1.30B
Total Liab.
$1.46B
Total Equity
-$162.8M
Cash
$615.8M
LT Debt
$385.1M
Book Value/Sh
$-2.69
Debt/Equity
-5.35x
Current Ratio
1.04
Quick Ratio
0.76
Returns & Growth
ROE
—
ROA
—
ROIC
-18.2%
Rev Growth YoY
+90.2%
EPS Growth YoY
+44.6%
Price Returns
2W
-8.7%
1M
-2.3%
3M
-4.0%
6M
+5.5%
12M
+37.6%
Technicals
52W High
$250.74
52W Low
$160.86
50d MA
$231.76
200d MA
$217.83
RSI (14)
56.10
ATR (14)
$8.52
Beta
0.48
Avg Volume
628K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$287.17
High
$342.00
Low
$250.00
Median
$267.50
Data updated apr 24, 2026 7:15pm
· Source: financialmodelingprep.com